Literature DB >> 30694380

Prognostic Accuracy of Three COPD Classification Systems in Relation to Long-Term Mortality of COPD Patients: A Prospective Multicenter Study.

Marek Plutinsky1, Kristian Brat2, Michal Svoboda3, Jaromir Zatloukal4, Patrice Popelkova5, Vladimir Koblizek6.   

Abstract

Recent research showed group B patients express higher mortality compared to group C patients when GOLD A-D grouping is used. We aimed to compare the prognostic accuracy of three GOLD classification systems, I-IV ("pre-2011"), A-D ("2011-2016") and A-D ("2017-present") in relation to mortality, exacerbation risk, quality of life (QoL) assessment and specific treatments use in a real-life COPD cohort. We used the data of 720 patients from the Czech Multicenter Research Database of COPD. Four-year mortality and time-to-exacerbation using the GOLD "pre-2011", "2011-2016" and "2017-present" classification schemes were assessed. Moreover, distribution of specific treatments use and QoL measures were analyzed. The GOLD I-IV classification system showed gradual increase in 4-year mortality across the stages (GOLD II 18.8%, III 28.5%, IV 38.7%) (p = 0.001). Using the A-D "2011-2016" classification scheme, group C patients had lower mortality (16.7%) than group B (18.7%) (p = 0.009). The A-D "2017-present" classification showed higher mortality in group B (25.5%) compared to group C (20%) (p = 0.05). For additional outcomes, the GOLD I-IV scheme showed highest match between the calculated 4-year exacerbation risk and QoL measures and GOLD stage/grouping. In terms of specific treatment distributions, various patterns for each GOLD classification system were observed with best match of GOLD "2017-present" system to the layout of GOLD groups and categories. We conclude the GOLD I-IV classification system had the highest accuracy related to mortality, QoL measures and exacerbation risk prediction, while the A-D "2017-present" scheme was most accurate within severity of symptoms prediction reflected also by more frequent specific treatments use.

Entities:  

Keywords:  COPD; GOLD classification; Mortality; Prognosis

Mesh:

Year:  2019        PMID: 30694380     DOI: 10.1007/s00408-019-00196-6

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  14 in total

1.  GOLD 2017 on the way to a phenotypic approach? Analysis from the Phenotypes of COPD in Central and Eastern Europe (POPE) Cohort.

Authors:  Neven Tudoric; Vladimir Koblizek; Marc Miravitlles; Arschang Valipour; Branislava Milenkovic; Adam Barczyk; Attila Somfay; Kirill Zykov; Kosta Kostov; Zuzana Zbozinkova; Michal Svoboda; Jurij Sorli; Alvils Krams; Ruzena Tkacova
Journal:  Eur Respir J       Date:  2017-04-26       Impact factor: 16.671

2.  Mortality after hospitalization for COPD.

Authors:  Pedro Almagro; Esther Calbo; Anna Ochoa de Echagüen; Bienvenido Barreiro; Salvador Quintana; José L Heredia; Javier Garau
Journal:  Chest       Date:  2002-05       Impact factor: 9.410

3.  Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification: a study of the general population.

Authors:  Peter Lange; Jacob Louis Marott; Jørgen Vestbo; Kim Rose Olsen; Truls Sylvan Ingebrigtsen; Morten Dahl; Børge Grønne Nordestgaard
Journal:  Am J Respir Crit Care Med       Date:  2012-09-20       Impact factor: 21.405

4.  Comparison of the 2017 and 2015 Global Initiative for Chronic Obstructive Lung Disease Reports. Impact on Grouping and Outcomes.

Authors:  Carlos Cabrera López; Ciro Casanova Macario; José María Marín Trigo; Juan P de-Torres; Rebeca Sicilia Torres; Jesús María González; Francesca Polverino; Miguel Divo; Víctor Pinto Plata; Javier J Zulueta; Bartolomé Celli
Journal:  Am J Respir Crit Care Med       Date:  2018-02-15       Impact factor: 21.405

5.  Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease.

Authors:  J J Soler-Cataluña; M A Martínez-García; P Román Sánchez; E Salcedo; M Navarro; R Ochando
Journal:  Thorax       Date:  2005-07-29       Impact factor: 9.139

Review 6.  FAQs about the GOLD 2011 assessment proposal of COPD: a comparative analysis of four different cohorts.

Authors:  Alvar Agusti; Suzanne Hurd; Paul Jones; Leonardo M Fabbri; Fernando Martinez; Claus Vogelmeier; Jørgen Vestbo; Robert Rodriguez-Roisin
Journal:  Eur Respir J       Date:  2013-05-03       Impact factor: 16.671

Review 7.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary.

Authors:  Klaus F Rabe; Suzanne Hurd; Antonio Anzueto; Peter J Barnes; Sonia A Buist; Peter Calverley; Yoshinosuke Fukuchi; Christine Jenkins; Roberto Rodriguez-Roisin; Chris van Weel; Jan Zielinski
Journal:  Am J Respir Crit Care Med       Date:  2007-05-16       Impact factor: 21.405

8.  Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD.

Authors:  Karin H Groenewegen; Annemie M W J Schols; Emiel F M Wouters
Journal:  Chest       Date:  2003-08       Impact factor: 9.410

9.  Respiratory parameters predict poor outcome in COPD patients, category GOLD 2017 B.

Authors:  Kristian Brat; Marek Plutinsky; Karel Hejduk; Michal Svoboda; Patrice Popelkova; Jaromir Zatloukal; Eva Volakova; Miroslava Fecaninova; Lucie Heribanova; Vladimir Koblizek
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-03-26

10.  Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort.

Authors:  Alvar Agusti; Lisa D Edwards; Bartolomé Celli; William Macnee; Peter M A Calverley; Hana Müllerova; David A Lomas; Emiel Wouters; Per Bakke; Steve Rennard; Courtney Crim; Bruce E Miller; Harvey O Coxson; Julie C Yates; Ruth Tal-Singer; Jørgen Vestbo
Journal:  Eur Respir J       Date:  2013-06-13       Impact factor: 16.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.